Health and Fitness Health and Fitness
Thu, August 30, 2012
[ Thu, Aug 30th 2012 ] - Market Wire
Lilly Announces Retirement of Robert Armitage, Na .. rington Senior Vice President and General Counsel
[ Thu, Aug 30th 2012 ] - Market Wire
Bayer Submits New Drug Application for Regorafeni .. eatment of Gastrointestinal Stromal Tumors (GIST)
[ Thu, Aug 30th 2012 ] - Market Wire
Exact Sciences to Participate in September Investor Conferences
[ Thu, Aug 30th 2012 ] - Market Wire
BioSante Pharmaceuticals, Inc. to Present at Stif .. ence and Rodman & Renshaw Global Investment Confe
[ Thu, Aug 30th 2012 ] - Market Wire
Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
[ Thu, Aug 30th 2012 ] - Market Wire
International Stem Cell Corp to Participate in Upcoming Investor Conferences
[ Thu, Aug 30th 2012 ] - Market Wire
Cerus to Present at the Baird Healthcare Conference on September 6, 2012
[ Thu, Aug 30th 2012 ] - Market Wire
ArQule, Inc. to Present at Upcoming Investment Conferences
[ Thu, Aug 30th 2012 ] - Market Wire
Bio-Reference Laboratories, Inc. Reports Best Qua .. in Corporate History with 25% Increase in Earning
[ Thu, Aug 30th 2012 ] - Market Wire
Affordable Hearing Aids Now Available to Millions of UnitedHealthcare Health Plan Customers
[ Thu, Aug 30th 2012 ] - Market Wire
Merger and Acquisition Activity Within the Biotech Industry Soars to a Four-Year High
[ Thu, Aug 30th 2012 ] - Market Wire
Trimel to Present at the Upcoming Investor Conferences
[ Thu, Aug 30th 2012 ] - Market Wire
Zynex Receives FDA 510(k) Clearance for InWave Medical Device
[ Thu, Aug 30th 2012 ] - Market Wire
Infinity to Present at Two Upcoming Conferences
[ Thu, Aug 30th 2012 ] - Market Wire
Dyax Corp. to Participate in the Rodman & Renshaw Annual Global Investment Conference
[ Thu, Aug 30th 2012 ] - Market Wire
Celsion to Present at Upcoming Investor Conferences in September
[ Thu, Aug 30th 2012 ] - Market Wire
ARIAD Announces Submission of Marketing Authoriza .. on for Ponatinib to the European Medicines Agency
[ Thu, Aug 30th 2012 ] - Market Wire
Transition Therapeutics Announces Dosing of First .. e 2 Clinical Study of ELND005 in Bipolar Disorder
[ Thu, Aug 30th 2012 ] - Market Wire
Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis
[ Thu, Aug 30th 2012 ] - Market Wire
Antares Pharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
[ Thu, Aug 30th 2012 ] - Market Wire
Given Imaging Announces Participation at the Morg .. thcare Unplugged Conference on September 10, 2012
[ Thu, Aug 30th 2012 ] - Market Wire
Isis Pharmaceuticals to Present at the 2012 Stifel Nicolaus Healthcare Conference
[ Thu, Aug 30th 2012 ] - Market Wire
Spectrum Pharmaceuticals to Present Corporate Upd .. care Conference in Boston on September 6th and at
[ Thu, Aug 30th 2012 ] - Market Wire
Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01
[ Thu, Aug 30th 2012 ] - Market Wire
Sucampo Pharmaceuticals Announces One-to-One Conv .. of Class B Common Stock into Class A Common Stock
[ Thu, Aug 30th 2012 ] - Market Wire
Capital Senior Living Corporation to Present at t .. ervices and Real Estate Conference on Thursday, S
[ Thu, Aug 30th 2012 ] - Market Wire
Teva Announces FDA Grants Approval for Tbo-filgra .. the Treatment of Chemotherapy-Induced Neutropenia
Wed, August 29, 2012
[ Wed, Aug 29th 2012 ] - Market Wire
Fox Paine Announces Sale of Paradigm
[ Wed, Aug 29th 2012 ] - Market Wire
The Law Firm of Wohl & Fruchter LLP Files Class Action Suit Against Assisted Living Concepts, Inc.
[ Wed, Aug 29th 2012 ] - Market Wire
Biogen Idec to Present at the Stifel Nicolaus Healthcare Conference 2012

Biogen Idec to Present at the Stifel Nicolaus Healthcare Conference 2012


Published on 2012-08-29 14:33:52 - Market Wire
  Print publication without navigation


WESTON, Mass.--([ ])--Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the Stifel Nicolaus Healthcare Conference 2012 will be webcast live on Wednesday, September 5, 2012 at 8:00 a.m. ET. To access the live webcast, please visit Biogen Idecas Investor Relations section ([ www.investor.biogenidec.com ]). An archived version of the webcast will be available for 14 days following the presentation.

About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the worldas oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit [ www.biogenidec.com ].

Contributing Sources